Targeted toxins consisting of the anti-EGFR scFv2112 from cetuximab or scFv1711 from panitumumab and the truncated version of Pseudomonas Exotoxin A (ETA’) were also tested against different tumor entities, including PCa. This evidence concerns the gene EGFR and neoplasm.